UK – NICE recommends Pfizer’s Paxlovid on NHS

Therapy will be available on the NHS as a clinical treatment option for adults with COVID-19

Pfizer has announced today that the National Institute for Health and Care Excellence (NICE) has issued an appraisal consultation document which recommends Paxlovid.

Also known as nirmatrelvir and ritonavir, the treatment is a clinical and cost-effective community therapy for eligible adults who have COVID-19 but do not require supplemental oxygen.

The drug also impacts individuals who are at risk of severe disease progression, as described by the independent advisory group report commissioned by the Department of Health and Social Care. In addition, this guidance supports making the antiviral treatment – which has been supplied to the UK Government since early 2022 – available throughout the NHS…